dc.contributor.author | Orkin, C | |
dc.contributor.author | Eron, JJ | |
dc.contributor.author | Rockstroh, J | |
dc.contributor.author | Podzamczer, D | |
dc.contributor.author | Esser, S | |
dc.contributor.author | Vandekerckhove, L | |
dc.contributor.author | Van Landuyt, E | |
dc.contributor.author | Lathouwers, E | |
dc.contributor.author | Hufkens, V | |
dc.contributor.author | Jezorwski, J | |
dc.contributor.author | Opsomer, M | |
dc.contributor.author | Grp, AMBERS | |
dc.date.accessioned | 2020-11-12T16:17:20Z | |
dc.date.available | 2020-11-12T16:17:20Z | |
dc.date.issued | 2020-04-01 | |
dc.identifier.issn | 0269-9370 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/68265 | |
dc.format.extent | 707 - 718 | |
dc.publisher | Wolters Kluwer Health, Inc | en_US |
dc.relation.ispartof | AIDS | |
dc.rights | Distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) | |
dc.subject | ART-naive | en_US |
dc.subject | darunavir | en_US |
dc.subject | cobicistat | en_US |
dc.subject | emtricitabine | en_US |
dc.subject | tenofovir alafenamide | en_US |
dc.subject | efficacy | en_US |
dc.subject | safety | en_US |
dc.subject | single-tablet regimen | en_US |
dc.title | Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients | en_US |
dc.type | Article | en_US |
dc.rights.holder | (c) 2019 The Author(s) | |
dc.identifier.doi | 10.1097/QAD.0000000000002463 | |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000524576600007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 5 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 34 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |